Pioneering diagnostics in dermatology and cancerbroad
DERMAGNOSTIX · Horizon Europe grant · 2022-10-01–2024-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
At Dermagnostix, we envision the next level for molecular diagnostics in human skin to improve patients’ lives and clinical practice in dermatology.Skin diseases are the 4th most relevant human illnesses according to loss of quality of life. Conventional diagnostics in dermatology based on clinical view and histopathology are imprecise and subjective, resulting in up to 50% of misdiagnosed cases and insufficient or harmful therapies. At Dermagnostix, we have developed a comprehensive technological platform for fast and objective molecular diagnostics in dermatology to reduce health care costs and improve patient treatment. Our fully automated platform delivers results within 90 min and testing can be run everywhere and at any time. Our easy-to-handle diagnostic device brings objective and precise skin diagnostics to reality allowing simultaneous detection of up to 40 different molecular targets within one single test.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| DERMAGNOSTIX GMBH | DE | coordinator | €2,499,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.